Europe hypophosphatasia treatment market is expected to reach USD 212.72 million by 2031, from USD 163.73 million in 2023 growing at the CAGR of 3.8% in the forecast period of 2024 to 2031.
Market Segmentation Europe Hypophosphatasia Treatment Market, By Types (Odontohypophosphatasia, Pseudohypophosphatasia, and Others), Therapy Type (Enzyme Replacement Therapy and Supportive Therapy), Route of Administration (Injectable and Oral), End User (Hospitals, Speciality Clinics, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Country (Germany, U.K., France, Italy, Spain, Netherlands, Belgium, Russia, Turkey, Switzerland, and rest of Europe) – Industry Trends and Forecast to 2031
Overview of Europe Hypophosphatasia Treatment Market Dynamics Drivers • Increasing incidence rate for hypophosphatasia • Continuous increase in clinical trials and pipeline products • Favorable reimbursement policies Restraints • High cost of treatment • Complex treatment regimen Opportunities • Increasing adoption of various types of advanced therapy • Initiatives by the government to create awareness Challenges • Impact of discontinuation of drug treatment and related adverse effect • Genetic variability and disease complexity
Market Players The key market players for Europe hypophosphatasia treatment market are listed below: • AstraZeneca • Pfizer Inc. • Abbott • Novartis AG • AM-Pharma B.V. • Be Biopharma • PuREC • Rallybio • Rampart Bioscience, Inc. • Roivant Sciences Ltd.
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
1 Introduction
1.1 Objectives Of The Study
1.2 Market Definition
1.3 Overview Of The Europe Hypophosphatasia Treatment Market
1.4 Currency And Pricing
1.5 Limitations
1.6 Markets Covered
2 Market Segmentation
2.1 Markets Covered
2.2 Geographical Scope
2.3 Years Considered For The Study
2.4 Dbmr Tripod Data Validation Model
2.5 Primary Interviews With Key Opinion Leaders
2.6 Multivariate Modelling
2.7 Market Application Coverage Grid
2.8 Product Lifeline Curve
2.9 Dbmr Market Position Grid
2.10 Vendor Share Analysis
2.11 Secondary Sources
2.12 Assumptions
3 Executive Summary
4 Premium Insights
4.1 Pestel Analysis
4.2 Porter’s Five Forces
4.3 Strategic Decisions
4.4 Patent Analysis
4.5 Product Sales By Year
5 Europe Hypophosphatasia (Hpp) Treatment Market: Regulations
5.1 U.S. Regulatory Scenario For Hypophosphatasia (Hpp) Treatment
5.2 Europe Regulatory Scenario For Hypophosphatasia (Hpp) Treatment
5.3 India
5.4 Middle East And Africa
6 Market Overview
6.1 Drivers
6.1.1 Increasing Incidence Rate For Hypophosphatasia
6.1.2 Continuous Increase In Clinical Trials And Pipeline Products
6.1.3 Favourable Reimbursement Policies
6.2 Restraints
6.2.1 High Cost Of Treatment
6.2.2 Complex Treatment Regimen
6.3 Opportunities
6.3.1 Increasing Adoption Of Various Types Of Advanced Therapy
6.3.2 Initiatives By The Government To Create Awareness
6.4 Challenges
6.4.1 Impact Of Discontinuation Of Drug Treatment And Related Adverse Effect
6.4.2 Genetic Variability And Disease Complexity
7 Europe Hypophosphatasia Treatment Market, By Types
7.1 Overview
7.2 Odontohypophosphatasia
7.3 Pseudohypophosphatasia
7.4 Others
8 Europe Hypophosphatasia Treatment Market, By Therapy Type
8.1 Overview
8.2 Enzyme Replacement Therapy
8.3 Supportive Therapy
9 Europe Hypophosphatasia Treatment Market, By Route Of Administration
9.1 Overview
9.2 Injectable
9.3 Oral
10 Europe Hypophosphatasia Treatment Market, By Distribution Channel
10.1 Overview
10.2 Hospital Pharmacy
10.3 Retail Pharmacy
10.4 Online Pharmacy
11 Europe Hypophosphatasia Treatment Market, By End User
11.1 Overview
11.2 Hospitals
11.3 Specialty Clinics
11.4 Others
12 Europe Hypophosphatasia Treatment Market, By Region
12.1 Europe
12.1.1 Germany
12.1.2 U.K.
12.1.3 France
12.1.4 Italy
12.1.5 Spain
12.1.6 Belgium
12.1.7 Russia
12.1.8 Netherlands
12.1.9 Turkey
12.1.10 Switzerland
12.1.11 Rest Of Europe
13 Europe Hypophosphatasia Treatment Market: Company Landscape
13.1 Company Share Analysis: Europe
14 Swot Analysis
15 Company Profile
15.1 Astrazeneca
15.1.1 Company Snapshot
15.1.2 Revenue Analysis
15.1.3 Company Share Analysis
15.1.4 Product Portfolio
15.1.5 Recent Development
15.2 Pfizer Inc.
15.2.1 Company Snapshot
15.2.2 Revenue Analysis
15.2.3 Company Share Analysis
15.2.4 Product Portfolio
15.2.5 Recent Developments
15.3 Abbott
15.3.1 Company Snapshot
15.3.2 Revenue Analysis
15.3.3 Company Share Analysis
15.3.4 Product Portfolio
15.3.5 Recent Developments
15.4 Novartis Ag
15.4.1 Company Snapshot
15.4.2 Revenue Analysis
15.4.3 Company Share Analysis
15.4.4 Product Portfolio
15.4.5 Recent Development
15.5 Am-pharma B.V.
15.5.1 Company Snapshot
15.5.2 Company Share Analysis
15.5.3 Product Portfolio
15.5.4 Recent Development
15.6 Be Biopharma
15.6.1 Company Snapshot
15.6.2 Product Portfolio
15.6.3 Recent Development
15.7 Purec.
15.7.1 Company Snapshot
15.7.2 Product Portfolio
15.7.3 Recent Development
15.8 Rallybio
15.8.1 Company Snapshot
15.8.2 Product Portfolio
15.8.3 Recent Developments
15.9 Rampart Bioscience, Inc.
15.9.1 Company Snapshot
15.9.2 Product Portfolio
15.9.3 Recent Development
15.10 Roivant Sciences Ltd.
15.10.1 Company Snapshot
15.10.2 Product Portfolio
15.10.3 Recent Development
16 Questionnaire
17 Related Reports
Table 1 Various Aspects Of Hypophosphatasia (Hpp)
Table 2 Targeted Treatment Of Hypophosphatasia
Table 3 Europe Hypophosphatasia Treatment Market, By Types, 2022-2031 (Usd Thousand)
Table 4 Europe Odontophosphatasia In Hypophosphatasia Treatment Market, By Region, 2022-2031 (Usd Thousand)
Table 5 Europe Pseudophosphatasia In Hypophosphatasia Treatment Market, By Region, 2022-2031 (Usd Thousand)
Table 6 Europe Others In Hypophosphatasia Treatment Market, By Region, 2022-2031 (Usd Thousand)
Table 7 Europe Hypophosphatasia Treatment Market, By Therapy Type, 2022-2031 (Usd Thousand)
Table 8 Europe Enzyme Replacement Therapy In Hypophosphatasia Treatment Market, By Region, 2022-2031 (Usd Thousand)
Table 9 Europe Supportive Therapy In Hypophosphatasia Treatment Market, By Region, 2022-2031 (Usd Thousand)
Table 10 Europe Hypophosphatasia Treatment Market, By Route Of Administration, 2022-2031 (Usd Thousand)
Table 11 Europe Injectable In Hypophosphatasia Treatment Market, By Region, 2022-2031 (Usd Thousand)
Table 12 Europe Oral In Hypophosphatasia Treatment Market, By Region, 2022-2031 (Usd Thousand)
Table 13 Europe Hypophosphatasia Treatment Market, By Distribution Channel, 2022-2031 (Usd Thousand)
Table 14 Europe Hospital Pharmacy In Hypophosphatasia Treatment Market, By Region, 2022-2031 (Usd Thousand)
Table 15 Europe Retail Pharmacy In Hypophosphatasia Treatment Market, By Region, 2022-2031 (Usd Thousand)
Table 16 Europe Online Pharmacy In Hypophosphatasia Treatment Market, By Region, 2022-2031 (Usd Thousand)
Table 17 Europe Hypophosphatasia Treatment Market, By End-user, 2022-2031 (Usd Thousand)
Table 18 Europe Hospitals In Hypophosphatasia Treatment Market, By Region, 2022-2031 (Usd Thousand)
Table 19 Europe Specialty Clinics In Hypophosphatasia Treatmentmarket, By Region, 2022-2031 (Usd Thousand)
Table 20 Europe Others In Hypophosphatasia Treatment Market, By Region, 2022-2031 (Usd Thousand)
Table 21 Europe Hypophosphatasia Treatment Market, By Country, 2022-2031 (Usd Thousand )
Table 22 Europe Hypophosphatasia Treatment Market, By Types, 2022-2031 (Usd Thousand )
Table 23 Europe Hypophosphatasia Treatment Market, By Therapy Type, 2022-2031 (Usd Thousand )
Table 24 Europe Hypophosphatasia Treatment Market, By Route Of Administration, 2022-2031 (Usd Thousand )
Table 25 Europe Hypophosphatasia Treatment Market, By End User, 2022-2031 (Usd Thousand )
Table 26 Europe Hypophosphatasia Treatment Market, By Distribution Channel, 2022-2031 (Usd Thousand )